The Fly | HALO

Halozyme

· HALO

Dashboard

Financials

KPIs

Ratios

Transcripts

Valuation

Monday

LifeMD partners with Halozyme subsidiary for exclusive testosterone program

Jun 22, 9:27 AM

Over a week ago

Halozyme price target lowered by $3 at Morgan Stanley, here's why

HALO

May 12, 8:05 AM

Halozyme still sees 2026 non-GAAP EPS $7.75 to $8.25, consensus $8.09

HALO

May 11, 4:04 PM

Halozyme reports Q1 non-GAAP EPS $1.60, consensus $1.52

HALO

May 11, 4:03 PM

Halozyme announces global collaboration and license agreement with GSK

May 7, 9:03 AM

Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis

May 6, 8:15 AM

Halozyme names Darren Snellgrove as CFO

Apr 30, 8:03 AM

Halozyme price target raised by $5 at H.C. Wainwright, here's why

HALO

Apr 29, 6:10 AM

Halozyme price target raised by $2 at Morgan Stanley, here's why

HALO

Apr 21, 8:43 AM

Halozyme enters global global collaboration and license agreement with Vertex

Apr 7, 8:02 AM

Halozyme names David Ramsay as Interim CFO

HALO

Mar 12, 8:31 AM

Halozyme price target raised by $16 at Morgan Stanley, here's why

HALO

Feb 19, 8:43 AM

Halozyme price target raised by $15 at Benchmark, here's why

HALO

Feb 19, 8:34 AM

Halozyme price target raised by $10 at Wells Fargo, here's why

HALO

Feb 19, 6:28 AM

Halozyme reaffirms FY26 non-GAAP EPS view $7.75-$8.25, consensus $8.18

HALO

Feb 17, 4:06 PM

Halozyme reports Q4 EPS 24c vs. $1.26 last year

HALO

Feb 17, 4:04 PM

Genmab sees 2026 revenue $4.065B-$4.395B, consensus $4.13B

Feb 17, 11:07 AM

Halozyme sees FY26 EPS $7.75-$8.25, consensus $8.21

HALO

Jan 28, 6:40 AM

Halozyme raises FY25 revenue view to $1.39B-$1.4B from $1.3B-$1.38B

HALO

Jan 28, 6:37 AM

Leerink views 'major deal' on Entyvio as positive for Halozyme

Jan 8, 1:38 PM

Halozyme price target raised by $11 at TD Cowen, here's why

HALO

Jan 8, 9:35 AM

Halozyme announces global collaboration, license agreement with Takeda

Jan 8, 8:05 AM

Halozyme price target lowered by $4 at Morgan Stanley, here's why

HALO

Jan 8, 7:39 AM

CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls

+16

Jan 6, 9:38 AM

Skye Bioscience, Halozyme enter collaboration, license agreement

Jan 5, 7:24 AM

Proprietary ENHANZE® Technology Platform: Halozyme's patented recombinant human hyaluronidase (rHuPH20) enzyme uniquely enables subcutaneous delivery of biologics, which otherwise require intravenous administration, providing a distinct technological edge.

Robust Strategic Partnership Network: The company licenses its ENHANZE platform to numerous global pharmaceutical leaders, including Roche, Takeda, Janssen, and AbbVie, validating its technology and ensuring diverse, long-term revenue streams from successful partner products.

High-Margin Royalty Revenue Model: Halozyme benefits from a lucrative business model primarily driven by recurring royalties from its partners' approved and commercialized products utilizing ENHANZE, providing a stable and high-profit revenue stream with minimal direct development costs.

Reliance on ENHANZE Platform: Halozyme's business model is heavily centered on its ENHANZE drug delivery technology. Any issues, limitations, or failure to secure new partnerships or expand existing ones for this platform could significantly impact future revenue and growth prospects.

Partnership Dependence and Termination Risk: A substantial portion of Halozyme's revenue comes from royalties and milestones from its collaborations with other pharmaceutical companies. The termination of existing agreements, a reduction in partner R&D efforts, or failure to secure new lucrative partnerships could adversely affect financial performance.

Clinical Development and Regulatory Approval Failures: While Halozyme's technology is primarily a delivery platform, its value is tied to the success of partner products. Clinical trial failures or regulatory rejections of partner drug candidates utilizing ENHANZE could reduce future royalty streams and impact the perceived value of the platform.